Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Recommendation of “Buy” from Brokerages

Posted by Stanley Muller on Aug 9th, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) has been given an average recommendation of “Buy” by the ten research firms that are currently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $46.4286.

A number of equities analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective on the stock. B. Riley Financial started coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price on the stock. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, June 15th.

Check Out Our Latest Research Report on AAPG

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth about $383,000. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, UBS Group AG boosted its stake in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Trading Up 11.1%

NASDAQ AAPG opened at $18.99 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. Ascentage Pharma Group International has a 1-year low of $16.36 and a 1-year high of $48.45. The stock has a 50-day moving average of $18.09 and a 200-day moving average of $21.72.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.